Xiao-bing B. Huang

No. 32, First Ring Road, P.R. China, 611072
Chengdu, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies.

Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies.

Journal: Stem cell reviews and reports

Published: November 03, 2025

Correction: Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.

Correction: Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.

Journal: Bone marrow transplantation

Published: January 06, 2025

Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study.

Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study.

Journal: Military Medical Research

Published: December 02, 2024

Comparison of outcomes between haploidentical and matched related donors for chronic myelomonocytic leukemia: A multicenter real-world study.

Comparison of outcomes between haploidentical and matched related donors for chronic myelomonocytic leukemia: A multicenter real-world study.

Journal: International journal of cancer

Published: October 10, 2024

Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study.

Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study.

Journal: Bone marrow transplantation

Published: September 24, 2024

A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study.

A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study.

Journal: Bone marrow transplantation

Published: July 06, 2024

Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.

Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.

Journal: Bone marrow transplantation

Published: May 20, 2024

The novel HLA-B*40:550 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

The novel HLA-B*40:550 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

Journal: HLA

Published: March 29, 2024

Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.

Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.

Journal: International journal of hematology

Published: November 23, 2023

Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML.

Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML.

Journal: American journal of hematology

Published: March 28, 2023

Initiation timing of veno-arterial extracorporeal membrane oxygenation

Initiation timing of veno-arterial extracorporeal membrane oxygenation

Journal: Zhonghua yi xue za zhi

Published: June 29, 2022

Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine.

Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 15, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026